GlassScriptPhysician profile
Namrata Patel
NPI 1548294283
$4,311.48
in general payments reported to CMS, 2019-2025
22 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,502 · 2020: $173 · 2021: $24.02 · 2023: $375 · 2024: $68.36 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.62 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,083.39 | 2019-2025 | Enhertu |
| Seagen INC. | $196.26 | 2019-2023 | Adcetris |
| Sirtex Medical INC | $147.12 | 2023 | Sir-Spheres Microspheres |
| Daiichi Sankyo INC. | $131.40 | 2020 | |
| Pfizer INC. | $125.00 | 2025 | |
| Cti Biopharma Corp. | $112.52 | 2023 | Vonjo |
| Emd Serono, INC. | $106.34 | 2019 | |
| Merck Sharp & Dohme LLC | $96.37 | 2019 | |
| Astellas Pharma US INC | $69.99 | 2019 | |
| Tempus Ai, INC | $68.36 | 2024 | |
| Amgen INC. | $31.51 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $15.76 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.32 | 2020 | |
| Celgene Corporation | $14.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.42 | 2019 | |
| Lilly USA, LLC | $12.30 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.10 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.98 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Genentech USA, INC. | $11.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namrata Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.